Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• High-risk neuroblastoma presents limited therapeutic strategies.
• Ferroptosis, a regulated cell death, is a potential anti-cancer mechanism.
• Natural compounds offer novel therapeutic avenues.

Purpose of the Study:

• To identify novel ferroptosis-inducing agents for high-risk neuroblastoma.
• To elucidate the mechanism of action of withaferin A in neuroblastoma.
• To evaluate the therapeutic potential of nano-targeted withaferin A.

Main Methods:

• In vitro and in vivo neuroblastoma models.
• Analysis of ferroptosis pathways, including nuclear factor-like 2 and glutathione peroxidase 4.
• Assessment of withaferin A efficacy compared to standard chemotherapies.
• Evaluation of nano-targeted withaferin A delivery.

Main Results:

• Withaferin A (WA) induces ferroptosis in high-risk neuroblastoma cells through a dual mechanism.
• WA activates the nuclear factor-like 2 pathway (noncanonical) and inactivates glutathione peroxidase 4 (canonical).
• This dual action leads to increased intracellular iron and cell death, surpassing etoposide and cisplatin efficacy.
• Nano-targeting of WA enhanced tumor accumulation and suppressed tumor growth and relapse in xenografts.

Conclusions:

• Withaferin A is a potent natural ferroptosis inducer for high-risk neuroblastoma.
• The novel double-edged ferroptosis mechanism contributes to WA's superior efficacy.
• Nano-targeted delivery of WA represents a promising therapeutic strategy for neuroblastoma.